The significant and growing global prevalence of diabetes continues to challenge people
with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Background Hybrid closed-loop insulin therapy has shown promise for management of type
1 diabetes during pregnancy; however, its efficacy is unclear. Methods In this multicenter …

Background Closed-loop control systems of insulin delivery may improve glycemic
outcomes in young children with type 1 diabetes. The efficacy and safety of initiating a …

Despite over 100 years of insulin therapy, glycemia remains suboptimal for many individuals
living with diabetes. Data from international diabetes registries highlight that most youth with …

Closed-loop (artificial pancreas) systems for automated insulin delivery have been likened
to the holy grail of diabetes management. The first iterations of glucose-responsive insulin …

Diabetes technologies represent a paradigm shift in type 1 diabetes care. Continuous
subcutaneous insulin infusion (CSII) pumps and continuous glucose monitors (CGM) …

Continuous glucose monitoring (CGM) technology has evolved over the past decade with
the integration of various devices including insulin pumps, connected insulin pens (CIPs) …

This chapter focuses on components of care unique to toddlers and preschool-aged children
with T1D. These guidelines are written for children with T1D aged 6 months to 6 years, but …

Objective: The safety and impact of the advanced hybrid closed-loop (AHCL) system on
glycemic outcome in 2-to 6-year-old children with type 1 diabetes and the diabetes distress …